Cargando…

Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers

BACKGROUND: Triple negative breast cancer (TNBC) is an aggressive breast cancer for which there is currently no targeted therapy. Tumor-infiltrating B-cells (TIB) have been observed in tumor tissues of TNBC patients, but their functional role is unclear. IgG4 is one of four antibody subclasses of Ig...

Descripción completa

Detalles Bibliográficos
Autores principales: Toney, Nicole J., Opdenaker, Lynn M., Cicek, Kader, Frerichs, Lisa, Kennington, Christopher Ryan, Oberly, Samuel, Archinal, Holly, Somasundaram, Rajasekharan, Sims-Mourtada, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900352/
https://www.ncbi.nlm.nih.gov/pubmed/35255925
http://dx.doi.org/10.1186/s12967-022-03319-5
_version_ 1784664094665605120
author Toney, Nicole J.
Opdenaker, Lynn M.
Cicek, Kader
Frerichs, Lisa
Kennington, Christopher Ryan
Oberly, Samuel
Archinal, Holly
Somasundaram, Rajasekharan
Sims-Mourtada, Jennifer
author_facet Toney, Nicole J.
Opdenaker, Lynn M.
Cicek, Kader
Frerichs, Lisa
Kennington, Christopher Ryan
Oberly, Samuel
Archinal, Holly
Somasundaram, Rajasekharan
Sims-Mourtada, Jennifer
author_sort Toney, Nicole J.
collection PubMed
description BACKGROUND: Triple negative breast cancer (TNBC) is an aggressive breast cancer for which there is currently no targeted therapy. Tumor-infiltrating B-cells (TIB) have been observed in tumor tissues of TNBC patients, but their functional role is unclear. IgG4 is one of four antibody subclasses of IgG expressed and secreted by B cells. Unlike other IgG isotypes, IgG4 has an immunosuppressive function and is induced by Th2-type cytokines. In cancers such as melanoma, IgG4 has been linked with advanced disease and poor patient survival. Therefore, we sought to determine if IgG4 + B cells are present and determine the mechanisms driving isotype switching in TNBC. METHODS: We performed co-culture assays to examine expression of Th2 cytokines by TNBC cells with and without the presence of B cells. We also performed in vitro class switching experiments with peripheral B cells with and without co-culture with TNBC cells in the presence or absence of an IL-10 blocking antibody. We examined expression of CD20(+) TIB, IgG4 and Th2 cytokines by immunohistochemistry in 152 TNBC samples. Statistical analysis was done using Log-Rank and Cox-proportional hazards tests. RESULTS: Our findings indicate that B cells interact with TNBC to drive chronic inflammatory responses through increased expression of inflammatory cytokines including the TH2 cytokines IL-4 and IL-10. In vitro class switching studies show that interactions between TNBC cell lines and B cells drive isotype switching to the IgG4 isotype in an IL-10 dependent manner. In patient tissues, expression of IgG4 correlates with CD20 and tumor expression of IL-10. Both IgG4 and tumor IL-10 are associated to shorter recurrence free survival (RFS) and overall survival (OS) in TNBC. In a multi-variant analysis, IL-10 was associated with poor outcomes indicating that tumor IL-10 may drive immune escape. CONCLUSIONS: These findings indicate that interactions between TIB and TNBC results in activation of chronic inflammatory signals such as IL-10 and IL-4 that drive class switching to an IgG4 + subtype which may suppress antibody driven immune responses. The presence of IgG4 + B cells may serve as a biomarker for poor prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03319-5.
format Online
Article
Text
id pubmed-8900352
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89003522022-03-17 Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers Toney, Nicole J. Opdenaker, Lynn M. Cicek, Kader Frerichs, Lisa Kennington, Christopher Ryan Oberly, Samuel Archinal, Holly Somasundaram, Rajasekharan Sims-Mourtada, Jennifer J Transl Med Research BACKGROUND: Triple negative breast cancer (TNBC) is an aggressive breast cancer for which there is currently no targeted therapy. Tumor-infiltrating B-cells (TIB) have been observed in tumor tissues of TNBC patients, but their functional role is unclear. IgG4 is one of four antibody subclasses of IgG expressed and secreted by B cells. Unlike other IgG isotypes, IgG4 has an immunosuppressive function and is induced by Th2-type cytokines. In cancers such as melanoma, IgG4 has been linked with advanced disease and poor patient survival. Therefore, we sought to determine if IgG4 + B cells are present and determine the mechanisms driving isotype switching in TNBC. METHODS: We performed co-culture assays to examine expression of Th2 cytokines by TNBC cells with and without the presence of B cells. We also performed in vitro class switching experiments with peripheral B cells with and without co-culture with TNBC cells in the presence or absence of an IL-10 blocking antibody. We examined expression of CD20(+) TIB, IgG4 and Th2 cytokines by immunohistochemistry in 152 TNBC samples. Statistical analysis was done using Log-Rank and Cox-proportional hazards tests. RESULTS: Our findings indicate that B cells interact with TNBC to drive chronic inflammatory responses through increased expression of inflammatory cytokines including the TH2 cytokines IL-4 and IL-10. In vitro class switching studies show that interactions between TNBC cell lines and B cells drive isotype switching to the IgG4 isotype in an IL-10 dependent manner. In patient tissues, expression of IgG4 correlates with CD20 and tumor expression of IL-10. Both IgG4 and tumor IL-10 are associated to shorter recurrence free survival (RFS) and overall survival (OS) in TNBC. In a multi-variant analysis, IL-10 was associated with poor outcomes indicating that tumor IL-10 may drive immune escape. CONCLUSIONS: These findings indicate that interactions between TIB and TNBC results in activation of chronic inflammatory signals such as IL-10 and IL-4 that drive class switching to an IgG4 + subtype which may suppress antibody driven immune responses. The presence of IgG4 + B cells may serve as a biomarker for poor prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03319-5. BioMed Central 2022-03-07 /pmc/articles/PMC8900352/ /pubmed/35255925 http://dx.doi.org/10.1186/s12967-022-03319-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Toney, Nicole J.
Opdenaker, Lynn M.
Cicek, Kader
Frerichs, Lisa
Kennington, Christopher Ryan
Oberly, Samuel
Archinal, Holly
Somasundaram, Rajasekharan
Sims-Mourtada, Jennifer
Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers
title Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers
title_full Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers
title_fullStr Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers
title_full_unstemmed Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers
title_short Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers
title_sort tumor-b-cell interactions promote isotype switching to an immunosuppressive igg4 antibody response through upregulation of il-10 in triple negative breast cancers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900352/
https://www.ncbi.nlm.nih.gov/pubmed/35255925
http://dx.doi.org/10.1186/s12967-022-03319-5
work_keys_str_mv AT toneynicolej tumorbcellinteractionspromoteisotypeswitchingtoanimmunosuppressiveigg4antibodyresponsethroughupregulationofil10intriplenegativebreastcancers
AT opdenakerlynnm tumorbcellinteractionspromoteisotypeswitchingtoanimmunosuppressiveigg4antibodyresponsethroughupregulationofil10intriplenegativebreastcancers
AT cicekkader tumorbcellinteractionspromoteisotypeswitchingtoanimmunosuppressiveigg4antibodyresponsethroughupregulationofil10intriplenegativebreastcancers
AT frerichslisa tumorbcellinteractionspromoteisotypeswitchingtoanimmunosuppressiveigg4antibodyresponsethroughupregulationofil10intriplenegativebreastcancers
AT kenningtonchristopherryan tumorbcellinteractionspromoteisotypeswitchingtoanimmunosuppressiveigg4antibodyresponsethroughupregulationofil10intriplenegativebreastcancers
AT oberlysamuel tumorbcellinteractionspromoteisotypeswitchingtoanimmunosuppressiveigg4antibodyresponsethroughupregulationofil10intriplenegativebreastcancers
AT archinalholly tumorbcellinteractionspromoteisotypeswitchingtoanimmunosuppressiveigg4antibodyresponsethroughupregulationofil10intriplenegativebreastcancers
AT somasundaramrajasekharan tumorbcellinteractionspromoteisotypeswitchingtoanimmunosuppressiveigg4antibodyresponsethroughupregulationofil10intriplenegativebreastcancers
AT simsmourtadajennifer tumorbcellinteractionspromoteisotypeswitchingtoanimmunosuppressiveigg4antibodyresponsethroughupregulationofil10intriplenegativebreastcancers